Cavinton forte - instructions for use, dose, side effects, contraindications

Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of neurons to hypoxia; enhancing glucose transport to the brain,through the blood-brain barrier; translates the process of the decay of glucose into an energetically more economical, aerobic pathway; selectively blocks Ca²⁺/ dependent phosphodiesterase (PDE); increases the levels of adenosine monophosphate (AMP) and cyclic guanosine monophosphate (cGMP) of the brain. Increases the concentration of ATP and the ratio of ATP / AMP in the brain tissues; enhances the metabolism of noradrenaline and serotonin of the brain; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect.

Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by red blood cells; helps to increase the oxygen release of red blood cells. Strengthens the neuroprotective effect of adenosine.

Increases cerebral blood flow; reduces the resistance of cerebral vessels without a significant change in the indices of the systemic circulation (blood pressure, minute volume, heart rate, total peripheral resistance). Not only does not have the effect of "stealing", but also enhances blood supply, especially in ischemic areas of the brain with low perfusion.

Pharmacokinetics:

Quickly absorbed, 1 hour after ingestion reaches the maximum concentration in the blood. Absorption occurs mainly in the proximal parts of the gastrointestinal tract. When passing through the wall of the intestine is not exposed to metabolism.

The maximum concentration in tissues is noted 2-4 hours after ingestion. The connection with proteins in the human body - 66%, bioavailability with ingestion - 7%. Clearance 66.7 l / h. exceeds the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism.

With repeated ingestions of 5 mg and 10 mg doses, the kinetics is linear. The half-life period in humans is 4.83 ± 1.29 hours. It is excreted in urine and calves in a ratio of 3: 2.

Indications:

Neurology: a decrease in the severity of neurological and mental symptoms in various forms of cerebral circulatory insufficiency (including post-ischemic stroke, reconstructive hemorrhagic stroke, the consequences of a stroke, transient ischemic attack, vascular dementia,vertebrobasilar insufficiency; atherosclerosis of cerebral vessels; posttraumatic and hypertensive encephalopathy).

Ophthalmology: chronic vascular diseases of the choroid and retina.

To treat hearing loss of the perceptive type, Meniere's disease, idiopathic tinnitus.

To avoid complications, use strictly according to the doctor's prescription.

Contraindications:

The acute phase of hemorrhagic stroke, severe form of coronary heart disease, severe arrhythmias and a known hypersensitivity to vinpocetine.

Pregnancy, tk. vinpocetine penetrates the placental barrier. At the same time, its concentration in the placenta and in the fetal blood is lower than in the pregnant woman's blood. At high doses, placental bleeding and spontaneous abortion are possible, probably as a result of increased placental blood supply.

Lactation period: within one hour, 0.25% of the accepted dose of the drug penetrates into breast milk. When using the drug, it is necessary to stop breastfeeding.

Children under 18 years (due to insufficient data)

Dosing and Administration:

The course of treatment and dosage is determined by the attending physician.

Inside, after eating.

Usually the daily dose is 15-30 mg (5-10 mg 3 times a day).

The initial daily dose is 15 mg. The maximum daily dose is 30 mg. The therapeutic effect develops about a week after the start of the drug. It takes three months to reach the full therapeutic effect.

With kidney and liver diseases the drug is prescribed in a usual dose, the absence of cumulation allows for long-term treatment.

Side effects:

Side effects on the background of the use of the drug were rarely detected.

From the side of the cardiovascular system: change in ECG (depression ST, lengthening the interval QT); tachycardia, extrasystole, however, the presence of a causal relationship is not proved. in a natural population, these symptoms are observed with the same frequency; lability of blood pressure, sensation of hot flashes.

From the central nervous system: sleep disturbances (insomnia, increased drowsiness), dizziness, headache, general weakness (these symptoms may be manifestations of the underlying disease), increased sweating.

From the side of the digestive system: dry mouth, nausea, heartburn.

Allergic skin reactions.

Overdose:

Currently, data on the overdose of vinpocetine are limited.

Treatment for overdose: gastric lavage, reception of activated charcoal, symptomatic therapy.

Interaction:

Interactions are not observed with simultaneous use with beta-blockers (chloranolol, pindolol), clopamid, glibenclamide, digoxin, acenocoumarol and hydrochlorothiazide, imipramine

Simultaneous use of Cavinton® Forte and methyldopy sometimes caused some strengthening of the hypotensive effect, therefore, such treatment requires regular monitoring of blood pressure.

Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when concurrently administering with the drugs central, antiarrhythmic and anticoagulant action.

Special instructions:To avoid complications, use strictly according to the doctor's prescription.

Presence of the syndrome of the prolonged interval QT and taking medications that elongate the interval QT, requires periodic ECG monitoring.

In case of lactose intolerance, it should be taken into account that one tablet contains 83 mg of lactose monohydrate.

Effect on the ability to drive transp. cf. and fur:DThere is no information about the impact of Cavinton® Forte on the ability to drive and work machinery.

Form release / dosage:

Tablets, 10 mg.

Packaging:

For 15 tablets in a blister of PVC and aluminum foil.

2 or 6 blisters in a cardboard box with instructions for use.

Storage conditions:

At a temperature of 15-30 ° C, in a place protected from light.

Keep out of the reach of children.

Shelf life:

5 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:П N014556 / 01

Date of registration:15.08.2007 / 26.01.2015

Expiration Date:Unlimited

The owner of the registration certificate:GEDEON RICHTER, OJSC GEDEON RICHTER, OJSC Hungary

Manufacturer: & nbsp

GEDEON RICHTER-RUS, CJSC Russia

GEDEON RICHTER, Ltd. Hungary

Representation: & nbspGEDEON RICHTER OJSC GEDEON RICHTER OJSC Hungary

Information update date: & nbsp27.11.2017

Illustrated instructions

Instructions

Cavinton® forte (Cavinton® forte)